A randomized competitive trial of Angiotensin II Receptor Blocker (ARB) for prevention of tumor recurrence in non-muscle invasive bladder cancer
Phase 3
Recruiting
- Conditions
- Bladder cancer
- Registration Number
- JPRN-UMIN000005044
- Lead Sponsor
- Keio University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1.Prior therapy of ARB and/or ACE inhibitor. 2.Normal blood pressure 3.Patients with primary CIS. 4.Presence of active other cancers. Having a severe complications occurred before this study; serious heart failure, renal failure, liver dysfunction, severe infection, and blood trouble. 5.Contraindications for ARB or Calcium channel blocker. (According to attached files of ARB or Calcium channel blocker.) 6.A pregnant women, a woman of breast-feeding, a woman who want to get pregnant. Presence of severe allergy for medicines.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-year recurrence-free survival rate
- Secondary Outcome Measures
Name Time Method Safety Quality of Life Overall survival